Lisata Therapeutics - Clinical-stage pharmaceutical Company

Cancer cells, 3D illustration

CendR Platform® Technology

The CendR Platform® incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer drugs to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.

Learn more about the CendR Platform®

Cell therapy close up rendering

CD34+ Cell Therapy Platform

Lisata’s proprietary CD34+ cell technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Through the administration of CD34+ cell therapy, the Company seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted areas.

Learn more about the CD34+ Cell Therapy Platform

Hand of male or female putting jigsaw puzzle connecting on woodden desk, Strategic management and business solutions for success

Spotlight

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

View press release

Spotlight

LSTA1 Mechanism of Action Explanation Video

Spotlight

Treating Pancreatic Tumors: Drug Delivery Systems & Pancreatic Cancer

Dr. Sugahara joined Dr. Hyesoo Lowe on an episode of Columbia Surgery’s podcast Conversations and Curbsides. The two doctors discuss the difficulty of treating pancreatic cancer tumors, and how drug delivery systems can potentially improve both chemotherapy and immunotherapy.

View transcription of the discussion

Spotlight

Congratulations to Bill Sietsema, PhD, VP of Global Regulatory Affairs at Lisata, who co-authored, “Regulation of Regenerative Medicines: A Global Perspective” and has been awarded the Regulatory Affairs Professionals Society (RAPS) Book of the Year. This book provides a comprehensive, up-to-date overview of global regulatory requirements for the rapidly evolving regenerative medicine landscape.

Access the book

Cell therapy scientist looking through a microscope

Broad, Clinical-Stage Pipeline

We aim to transform patient lives through the development of unique therapies targeting cancer and other serious diseases.

Explore our pipeline

Pipeline

News

Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

News

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

News

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Join Our Team

Our mission is to discover, develop and deliver innovative therapies for the treatment of advanced solid tumors and other major diseases. We can accomplish that goal through the collective efforts of talented individuals who work together to advance scientific research. We place a premium on integrity, respect, diversity, and collaboration. These values have helped us to build a growing company that offers professionally rewarding careers with the opportunity to make a meaningful contribution to patients in need.

Learn more about Lisata's career opportunities

Lisata career interviewer reviewing a candidates resume